Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

First human implants of Biotectix's BT DOT coated electrodes

Biotectix : 20 January, 2012  (Company News)
Biotectix, an Allied Minds subsidiary, completes the first-in-human (FIH) use of an electrostimulation device incorporating its BT DOT conductive polymer coating technology.
Last month, patients were surgically implanted with novel gastric stimulation devices utilising electrodes coated with Biotectix's proprietary material. The FIH achievement represents a step toward commercialization of a core Biotectix product, BT DOT. Biotectix also continues to work with a number of partners developing the next generation of chronically implanted electrical stimulation and recording devices for a variety of applications.



Dr Jeffrey Hendricks, Director of Engineering at Biotectix, was present during the surgical procedures and noted: "The BT DOT coating allowed our partner to use a much smaller electrode and lead assembly than they have previously implanted. The assembly was also easier and faster for the surgeon to implant, which should result in reduced trauma to the patient, more reproducible orientation, and better placement. Early results also suggested the coated electrodes may enable faster and more effective stimulation of the GI tract."



The trial is the culmination of several months of activity with the device partner, from initial development and demonstration of the BT DOT coating on prototype designs in vitro to completion of stability, sterilization, and durability testing. In the final phases, devices suitable for human uses were prepared and necessary IRB documentation was submitted and approved prior to initiation of the study. Treatment of additional patients is anticipated in the coming months.



Dr James Arps, General Manager at Biotectix, remarked: "The first human implants of devices incorporating the BT DOT technology is a tremendous accomplishment for Biotectix in demonstrating the safety and efficacy of our proprietary coating materials. This is the first of a number of successful clinical studies that we hope to complete with our various partners in the coming year."
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo